Delhi Court Dismisses Teva Infringement Suit Against Natco for Lack of Jurisdiction

摘要

The Delhi High Court Feb. 28 dismissed a plea by Israel-based Teva Pharmaceutical Industries for a permanent injunction to restrain Indian generic drug maker Natco Pharma Ltd from selling a copy of Teva's multiple sclerosis drug Copaxone in the U.S. (Case CS (OS) No. 3193 of 2012). Teva's petition had claimed that Natco's copy of the drug, whose generic name is glatiramer acetate, violated Indian process patent No. 190759 owned by Teva's partner Yeda Research and Development Company Ltd.